Novavax Reports First Quarter 2021 Financial Results and Operational Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. USO
2. CHRW
3. MRVL
4. RXO
5. OPCH
6. NVDA
7. APLD
8. SPY
9. AMD
10. GOOGL

Go back to Novavax Reports First Quarter 2021 Financial Results and Operational Highlights

JPMorgan Downgrades Novavax (NVAX) to Neutral

May 12, 2021 5:45 AM EDT

JPMorgan analyst Eric Joseph downgraded Novavax (NASDAQ: NVAX) from Overweight to Neutral with a price target of $161.00 (from $285.00).

The analyst comments "We are rated Neutral on NVAX shares. While topline UK phase 3 results reported to date have shown compelling efficacy, amid a series of clinical,... More

Novavax (NVAX) Tops Q1 EPS by 55c, Revenues Beat

May 10, 2021 4:04 PM EDT

Novavax (NASDAQ: NVAX) reported Q1 EPS of ($3.05), $0.55 better than the analyst estimate of ($3.60). Revenue for the quarter came in at $447.23 million versus the consensus estimate of $233.9 million.

"Novavax made great strides over the first quarter to pave the path for our COVID-19 vaccine candidate, NVX-CoV2373,... More